ENTA – enanta pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting [Yahoo! Finance]
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
Form EFFECT ENANTA PHARMACEUTICALS
Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Kowalsky Matthew Paul
Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Luu Brendan
Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Kieffer Tara Lynn
Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Rottinghaus Scott T.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.